Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6547367rdf:typepubmed:Citationlld:pubmed
pubmed-article:6547367lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C0032952lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C0055985lld:lifeskim
pubmed-article:6547367lifeskim:mentionsumls-concept:C1705294lld:lifeskim
pubmed-article:6547367pubmed:issue6lld:pubmed
pubmed-article:6547367pubmed:dateCreated1984-8-2lld:pubmed
pubmed-article:6547367pubmed:abstractTextForty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone. Methotrexate (200 mg/m2) was given iv 1 hour before administering 5-FU (600 mg/m2). Leucovorin (10 mg orally every 6 hours for six doses) was begun 24 hours after the methotrexate. The response rate was 43%, with 19% of patients having a clinically complete remission. This overall objective response rate is lower than that achieved when this drug combination is given at standard doses of methotrexate and with no interval before 5-FU. Toxicity was primarily related to bone marrow suppression; eight women had wbc counts that fell to less than 1500/mm3.lld:pubmed
pubmed-article:6547367pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:languageenglld:pubmed
pubmed-article:6547367pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:citationSubsetIMlld:pubmed
pubmed-article:6547367pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6547367pubmed:statusMEDLINElld:pubmed
pubmed-article:6547367pubmed:monthJunlld:pubmed
pubmed-article:6547367pubmed:issn0361-5960lld:pubmed
pubmed-article:6547367pubmed:authorpubmed-author:HortonJJlld:pubmed
pubmed-article:6547367pubmed:authorpubmed-author:TaylorS...lld:pubmed
pubmed-article:6547367pubmed:authorpubmed-author:GlickJ HJHlld:pubmed
pubmed-article:6547367pubmed:authorpubmed-author:CadmanE CEClld:pubmed
pubmed-article:6547367pubmed:authorpubmed-author:CrossJJlld:pubmed
pubmed-article:6547367pubmed:issnTypePrintlld:pubmed
pubmed-article:6547367pubmed:volume68lld:pubmed
pubmed-article:6547367pubmed:ownerNLMlld:pubmed
pubmed-article:6547367pubmed:authorsCompleteYlld:pubmed
pubmed-article:6547367pubmed:pagination877-9lld:pubmed
pubmed-article:6547367pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:meshHeadingpubmed-meshheading:6547367-...lld:pubmed
pubmed-article:6547367pubmed:year1984lld:pubmed
pubmed-article:6547367pubmed:articleTitleSequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.lld:pubmed
pubmed-article:6547367pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6547367pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed